Lates News

date
08/02/2026
On November 13th, the official website of the China Drug Administration (CDE) announced that the new indication application for the Glucagon-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) dual receptor agonist Tirzepatide injection of Eli Lilly (LLY.N) has been accepted. This is the third indication approved for the drug in China after receiving approval for another indication.
Latest
See all latestmore